In this study, whey protein was hydrolyzed by trypsin. A calcium binding peptide was isolated and purified by ultra-filtration, gel filtration chromatography, and reverse phase HPLC from the hydrolysate. The target peptide, with a molecular weight of 555.54 Da and with the amino acid sequence Ser-Thr-Glu-Tyr-Gly, corresponds to the 48 to 52 th amino acid sequence of bovine α-lactalbumin, which exhibited a significant effect on promoting the absorption of calcium in mice. The peptide could be used as a food additive to prevent calcium deficiency in humans.
INTRODUCTION
Whey is composed of proteins, lactose, various salts and vitamins, water, and low molecular weight compounds. Whey proteins represent probably 20% of the total bovine milk proteins. [1] The major known fractions of whey proteins are α-lactalbumin, β-lactoglobulin, immunoglobulin, and bovine serum albumin. [2] Although whey is a good source of protein, it is only used as a food ingredient for animals and humans in the form of nutritional supplements. Calcium, the most abundant mineral in the human body, has several important functions, such as muscle contraction, hormone secretion, and message transmission through the nervous system. However, calcium is usually deficient in most diets. When calcium intake is low or poorly absorbed, bone disorders occur. [3] The most common source of calcium in the modern diet is from dairy products. However, lactose intolerant people can consume small levels of dairy products throughout the day. Because of China's plant-based food dietary pattern and limited consumption of dairy products, calcium deficiencies are common. [4] Therefore, the development of a functional food that enhances the body's absorption of calcium may alleviate some Ca deficiencies.
Among the mineral-binding peptides derived from the digestion of milk proteins, casein phosphopeptides have been extensively investigated. [5] [6] [7] However, studies on the utilization of whey proteins as producing mineral carrier peptides are scarce. Therefore, in 1128 PAN, LU, AND ZENG the present study, a calcium binding peptide was isolated and purified from whey protein, the amino acid sequence of the calcium-binding peptide determined, and its effects on bone density and femoral calcium content of growing mice examined.
MATERIALS AND METHODS

Materials and Chemicals
The whey protein concentrate (WPC) used in this study was obtained from the Dairy Factory of Capital Agribusiness Group (Beijing, China). ICR mice were purchased from Nanjing Medical University (Nanjing, China). Bovine trypsin (250 U/mg solid) was purchased at Sigma Chemicals Co. Ltd. (St. Louis, MO, USA). DEAE-Sephadex A-25, Sephadex G-15, acetonitrile, and TFA were purchased from Ameresco Company (St. Louis, MO, USA). The other chemicals were purchased from Nanjing Chemical Company (Nanjing, China) and were analytical grade.
Preparation of Whey Protein Hydrolysates
WPC solution was prepared by dissolving 7.0% (w/w) WPC in deionized water. This WPC solution was defatted by ultracentrifugation at 8000× g for 20 min. The pH of the prepared WPC solution was adjusted to 8.0 with 0.5 M NaOH prior to the addition of bovine trypsin with an enzyme:substrate ratio of 1:70 (w/w). The mixture was incubated at 45
• C in the hydrolysis process. The pH was adjusted every 10 min to maintain a constant pH of 8.0, and the Ca binding capacity of hydrolysate was determined at every 20 min. Hydrolysis was stopped by heating the reaction mixture at 100
• C for 5 min to inactivate the enzyme when the strongest Ca-binding capacity of hydrolysate was obtained. The reaction mixture was centrifuged at 5000× g for 15 min, and the supernatant was filtered using a hollow fiber membrane with a molecular weight cutoff of 3000 Da (Shanghai Mosutech Co. Ltd., Shanghai, China). The membrane filtered solution was lyophilized and used as WPC hydrolyzate powder for further purification. The degree of hydrolysis was determined using the trinitrobenzene sulfornic acid assay, [8] and Ca binding activity was measured using the method as described by Wheeler et al. [9] Determination of Ca Binding Capacity Ca binding capacity of the WPC hydrolyzate and peptide were examined by the inhibition of calcium carbonate precipitation from supersaturated solutions. [9] Formation of calcium carbonate precipitates was followed by recording the turbidity of a solution containing 100 μL of 22 mM NaHCO 3 (pH 8.7) and 20 μL sample solution after 100 μL of 22 mM CaCl 2 were added to the solution. Changes in turbidity of the solution were measured every minute for 6 min by the absorbance at 570 nm with a spectrophotometer.
Purification of Ca Binding Peptides
The WPC hydrolyzate powder was dissolved in 50 mM Tris-HCl buffer (pH 9.0). The solution was loaded onto a DEAE-Sephadex A-25 (2.6 cm ×100 cm) column (Sigma Co., Ltd., Shanghai, China). After incubation, the column was eluted with the 50 mM TrisHCl buffer (pH 9.0) at 1.0 ml/min flow rate. The eluate was monitored for peptide content by measuring the absorbance at 220 nm. After the Ca binding capacity of each fraction from the DEAE-Sephadex A-25 column was determined, the fractions having the highest Ca binding activity were pooled, lyophilized, and used as a crude Ca binding peptide. This crude Ca binding peptide was dissolved in distilled water and loaded onto a Sephadex G-15 (1.6 cm × 50 cm) column. After incubation, the column was eluted with the 50 mM Tris-HCl buffer (pH 9.0) at 1.0 ml/min flow rate. Meanwhile, the eluate was monitored by measuring the absorbance at 220 nm. After the Ca binding capacity of each fraction from Sephadex G-15 was determined, the fractions with the highest Ca binding activity were further purified through reversed-phase high performance liquid chromatography (RP-HPLC).
Reversed-Phase High Performance Liquid Chromatography (RP-HPLC)
The RP-HPLC system was equipped with a quaternary gradient pumping system, in-line degasser, variable wavelength absorbance detector set at 220 nm, and automatic injector (1200 Series, Agilent Technologies, Santa Clara, CA, USA). RP-HPLC was performed on a semi-preparative Agilent ZORBAX Eclipse XD8 C 18 column (150 × 21.2 mm, 7 mm, Agilent Technologies), equilibrated with solvent A (0.1% TFA in H 2 O). The sample was then injected and the column was eluted with a linear gradient to 80% solvent B (60% acetonitrile, 40% H 2 O, 0.1% TFA) during the first 15 min, to 0% in the next 5 min, and the column was re-equilibrated with 100% solvent A for 20 min. The flow rate was 1 ml/min. The fractions were concentrated by lyophilization, Ca binding activity was determined, and peptide concentration was measured using trinitrobenzene sulfornic acid (TNBS) assay. The fraction with the highest Ca binding activity was used for peptide sequencing and the animal experiment.
Analysis of Amino Acid Sequences of Ca Binding Peptides
The molecular mass of the peptides purified by RP-HPLC with the highest Ca binding activity was determined using a triple-quadruple mass spectrometer (TSQ, Finnigan MAT, San Jose, CA, USA). The sequences were determined by Secondary Ion Mass Spectrometry performed with the same system. Samples were dissolved to a concentration of approximately 10 ppm in methanol, and analyzed by infusion of the samples (10 μL) through electrospray interface. Ion source and polarity were electrospray ionizationed (ESI) and capillary temperature was set at 350
• C. Spray voltage was 4000 V. Nitrogen was used as sheath and aux gas. Sheath and aux gas pressures were 35 arb and 3 arb, respectively. Argon was used as the target gas (3 m Torr) for the collision. Collision energy was set at 20-30 V. Mass spectra were acquired over 30 to 1000 m/z. Peptide identification involved in the search for the masses in the NCBI database of bovine whey proteins and matched the MS/MS spectrum with the sequences selected by mass. GPMAW 8.0 software (Engvej 35, DK-5230, Odense M, Denmark) and a Mascot server were used to identify the peptide sequences.
Experimental Animals and Diets
All experiments were performed with male ICR mice of 20-22 g provided by Nanjing Medical University of China and kept to acclimatize for 1 week before the experiments. The mice were housed under a 12 h light and 12 h darkness cycle at 22 ± 2
• C, with a relative humidity of 75 ± 10%. The mice were randomly divided into four groups. Each group consisted of 12 mice. The basis diet was composed of 54.0% wheat flour, 15.0% soybean powder, 11.0% starch, 10.0% whey protein, 4.0% corn oil, 2.60% mixed salts, 2.0% cellulose, 1.0% mixed vitamins, 0.20% choline chloride, and 0.20% DL-methionine; the content of calcium in the basis diet was 640 mg/kg. Group 1 received basis diet served as the low calcium control. Group 2 received basis diet and calcium carbonate (650 mg/kg body weight), served as the normal calcium control. Group 3 received basis diet and peptides (50 mg/kg body weight), served as the low dose experimental group. Group 4 received basis diet and peptides (100 mg/kg body weight), served as the high dose experimental group. Diet and distilled water were freely accessible; the calcium carbonate and peptide dissolved in de-mineralized water were administered intragastrically once a day throughout the experimental periods. Body weights and amount of diet taken were recorded weekly during experimental periods of 28 days.
Determination of Bone Calcium Content and Density
Mice were sacrificed, and both femurs of the test mice were removed. Muscles and connective tissues attached to the femurs were also removed. Wet and dry (105
• C in an oven to a constant weight) weight of the femurs were recorded. After the bone was heated at 580
• C for 8 h, ash was dissolved in 10 mL of 6 N HCl. The suspension was filtered through Whatman No. 41 filter paper. Calcium content was determined using atomic absorption spectrometry. [10] Bone volume and density were measured by Archimedes' principle. [11] Briefly, each bone was put in an unstoppered vial filled with deionized water, and the vial was placed under a vacuum for 90 min to ensure that all trapped air was diffused out of the bone. Each bone was removed from its vial, blotted with a gauze sponge, weighed, and returned to the vial containing deionized water. The bone was reweighed in water and the density (Q 1 ) was calculated according to the formula: Q 1 = (A/P) × Q 0 (g/cm 3 bone volume), where Q 0 is the density of water, A is the femoral weight in the air, and P is the buoyancy in the water.
Statistical Analysis
Statistical analysis was performed by t-test with software SPSS 14.0 (International Business Machines Corporation, Armonk, NY, USA). All experiments were performed in triplicate and experimental results shown were expressed as means ± SD.
RESULTS AND DISCUSSION
Separation and Amino Acid Sequences of Ca Binding Peptide
WPC hydrolysates were fractionated on gel filtration chromatography. There were seven major peaks from DEAE-Sephadex A-25 column chromatography (Fig. 1) . Ca binding capacity of each fraction was determined accordingly. As fraction 6 showed the strongest Ca binding capacity, it was selected and loaded onto the Sephadex G-15 column for further purification. There were three major fractions separated during the gradient elution (Fig. 1) . Based on the data from Ca binding capacity assay and peptide concentration of each fraction, fraction 3 with a strong Ca binding capacity was collected, concentrated, and re-fractionated in reversed-phase high performance liquid chromatography (RP-HPLC). As shown in Fig. 1 , two fractions were obtained. Calcium carbonate precipitation inhibition assay of fraction 1 and 2 separated by RP-HPLC showed that fraction 1 significantly inhibited calcium carbonate precipitation compared to fraction 2 (Fig. 2) . These results suggested that fraction 1 contained organic matrices associated with Ca binding. Fraction 1 was designated as the Ca binding peptide and was used for amino acid sequencing and an animal experiment.
The Ca binding fraction 1 contained a peptide that had an amino acid sequence of Ser-Thr-Glu-Tyr-Gly (STEYG) (Fig. 3) . The STEYG sequence had a molecular weight of 555.54 Da. The result was confirmed by comparing it with the data from the National Center for Biotechnology Information (NCBI) database. This STEYG sequence of the Ca binding peptide was also found in bovine α-lactalbumin (from 48th to 52nd amino acid); this means that the peptide is released from α-lactalbumin. Table 1 shows that the bone density of femurs from the low and high Ca binding peptide dosage experimental groups (3 and 4 groups) was higher than those of femurs from the low calcium (group 1) and normal calcium control (group 2). The femur density from the low dose Ca binding peptide experimental (group 3) were significantly higher than that of femurs from the low calcium control (group 1) (P < 0.05). There was a significant difference in the femurs' density between the high dose of Ca binding peptide (group 4) and low calcium control (group 1) (P < 0.01). Compared to the normal calcium control (group 2), the bone density of the high dose Ca binding peptide (group 4) was significantly higher (P < 0.05). Thus, dose dependent effects of peptide on femur density could be found in mice after administration of the Ca binding peptides. However, there was no significant difference in femur density of mice between the normal calcium control (group 2) and low calcium control (group 1) (P > 0.05). Present experimental results demonstrate that the bone density of the Ca binding peptide supplemented mice were significantly higher than those of the mice without Ca binding peptide supplement.
Ca Binding Peptide on Bone Density in Mice
Ca Binding Peptide on Femoral Dry Weight and Calcium Content in Mice
As shown in Table 1 , the femoral dry weight of the calcium control (group 2) and the Ca binding peptide experimental (group 3 and 4) were higher than that of the low calcium control (group 1). The femoral dry weight of the experimental group with a high dose of Ca binding peptide was significantly larger than those of low calcium control and calcium control. The femoral calcium content of the low dose of Ca binding peptide experimental group was significantly higher compared to the low calcium control (P < 0.05), and the femoral calcium content of the high dose of Ca binding peptide experimental was significantly higher than that in the low calcium and calcium control (P < 0.01). This suggests that the Ca binding peptide may promote calcium deposition in femurs. The dry weight of the femur from the mice that received a higher Ca binding peptide supplement was clearly higher than that of the femur from the mice without Ca binding peptide supplement. This indicates that there exists an effect on promoting calcium absorption when mice are fed with whey protein derived Ca binding peptide.
Glu residues may be the major amino acid associated with Ca binding. [12] [13] [14] The present results show that the target peptide of Ser-Thr-Glu-Tyr-Gly contains serine, threonine, glutamic acid, tyrosine, and glycine. Thr, Tyr, and Ser are known as major sites for phosphorylation and combination with metal ions, [15] so the H in hydroxyl may be replaced by phosphate groups to become phosphorylated serine, threonine, and tyrosine, functioning in binding minerals with the help of the free carboxyl groups of glutamate. Hence, they might exert an influence on the absorption of calcium and other minerals in the intestine. However, the mechanism of Ca binding function of the peptide needs to be further studied.
CONCLUSION
In summary, a Ca binding peptide from bovine α-lactalbumin hydrolysates was isolated and purified using hollow fiber membrane filtration, DEAE-Sephadex A-25, Sephadex G-15, and RP-HPLC chromatography, and its amino acid sequence was identified as SerThr-Glu-Tyr-Gly by LC/ESI tandem mass spectrometry. The peptide may increase bone density and calcium content in growing mice.
